Stenting the ureteroneocystostomy reduces urological complications in kidney transplantation: a noninferiority randomized controlled trial, SPLINT trial by Ooms, L.S.S. (Liselotte) et al.
ORIGINAL ARTICLE
Stenting the ureteroneocystostomy reduces
urological complications in kidney transplantation:
a noninferiority randomized controlled trial, SPLINT
trial
Liselotte S. S. Ooms1 , Robert C. Minnee1, Frank J. M. F. Dor1, Diederik J. A. N. Kimenai1,
Khe C. K. Tran1, Hermien Hartog1, Jacqueline van de Wetering2, Sten P. Willemsen3,
Jan N. M. IJzermans1 & Turkan Terkivatan1
1 Department of Surgery, Erasmus
MC, University Medical Center,
Rotterdam, The Netherlands
2 Department of Nephrology,
Erasmus MC, University Medical
Center, Rotterdam, The Netherlands
3 Department of Biostatistics,
Erasmus MC, University Medical
Center, Rotterdam, The Netherlands
Correspondence
Dr. Turkan Terkivatan, Department of
Surgery, Erasmus MC, University
Medical Center, PO BOX 2040 3000
CA Rotterdam, the Netherlands.
Tel.: +31 10 704 0 704;
e-mail: t.terkivatan@erasmusmc.nl
The trial was registered at the (Dutch)
Netherlands Trial Registry: Trial
NL4358 (NTR4498).
SUMMARY
The role of ureteral stents in living-donor kidney transplantation remains
uncertain. In this randomized controlled trial (SPLINT), we compared
urological complications in living-donor kidney transplantations performed
with or without stents. We included 200 consecutive patients that received
living-donor kidney transplantations at the Erasmus MC, University Medi-
cal Center, Rotterdam. Patients (124 males, 76 females, mean age 54  13)
were randomized for suprapubic externalized single J stents (N = 100) or
no stent (N = 100). The primary outcome was the probability of a percu-
taneous nephrostomy insertion (PCN) during a 12-month follow-up. To
assess whether no stenting is noninferior to stenting, we allowed the proba-
bility of a PCN to increase by at most 5% (this is the noninferiority
margin). Baseline characteristics were comparable between groups. In the
no-stent group, there were more PCN insertions, 14% (95% CI 4.3–
23.7%); urinary leakages, 12% (95% CI 5.4–21.3%); and surgical re-inter-
ventions because of urological complications, 8% (95% CI 1.5–14.5%).
The stent group had more hematuria, 26% (95% CI 13.1–38.9%); and
graft rejections, 15% (95% CI 2.7–27.3%). Patients in both groups had
similar mean GFRs at several time points. Besides a better Euro-Qol-5D in
the no-stent group at 2 and 6 weeks postoperative, similar quality of life
was reported based on SF-36 and Euro-Qol-5D scores. In this trial, nonin-
feriority has not been demonstrated for no-stent placement in relation to
the number urological complications.
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Introduction
Kidney transplantation is the optimal treatment offering
long-term benefits to the majority of patients with
chronic kidney failure. However, urological complica-
tions after kidney transplantation, such as urinary leak-
age and ureteral strictures, are associated with
significant morbidity, surgical and radiological
ª 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd. 1
doi:10.1111/tri.13638
Transplant International
interventions, prolonged hospital stays, and even mor-
tality. Most urological complications are related to the
ureteroneocystostomy, and they are treated with a per-
cutaneous nephrostomy (PCN) [1,2].
The role of ureteral stents in living-donor kidney
transplantations remains uncertain. A Cochrane review,
published in October 2005 and revised in 2013, suggests
that routine prophylactic stenting reduces the incidence
of major urological complications. However, there are
some limitations to this Cochrane review. First of all,
most included studies are from 1995 to 2000. As in the
last 20 years many improvements have been made in
the immunosuppressive treatment, we wonder how rep-
resentative these data are for current medicine. Secon-
darily, different kinds of stents (lengths and caliber)
have been used and none of them include an external-
ized stent. Furthermore, the study designs of the seven
included articles were heterogeneous with different types
of donors, intervention periods, outcome assessments,
and statistical analysis [3,4]. Stent placement also has
some disadvantages. The complications associated with
stents include infections, obstructions, stent migrations,
breakage, stone formation, hematuria, and secondary
ureteral obstructions [4–9].
In this trial (Stent PLacement IN living-donor kidney
Transplantation, SPLINT), we tested the hypothesis that
omitting a ureteral stent in kidney transplantation
might be as effective as stenting, and it might even
reduce the number of urological complications, because
of the absence of stent-related problems. We also fol-
lowed patients for 1 year to evaluate quality of life
(QOL).
Methods
Study design
In this randomized controlled trial, we included all
patients that received a living-donor kidney transplanta-
tion at the Erasmus MC, University Medical Center,
Rotterdam, the Netherlands, between April 2014 and
March 2017. Exclusion criteria were as follows: declined
informed consent, age <18 years, a reconstructed uri-
nary tract or conduit after total or partial cystectomy,
bladder dysfunction that required continuous or inter-
mittent catheterization, and a donor kidney with dupli-
cated ureters. Patients with primary focal segmental
glomerulosclerosis (FSGS) that still had residual urinary
output were also excluded. FSGS is known to recur
rapidly in kidney grafts, in which case the first sign is
proteinuria. An externalized stent allows one to
distinguish whether proteinuria originated in the trans-
planted kidney or the native kidneys. Furthermore, we
excluded recipients that were included in another ongo-
ing clinical trial.
We randomized 200 patients to either stent place-
ment (N = 100, Teleflex, suprapubic externalized sin-
gle J stent, 7 fr) or no-stent placement (N = 100). In
our center, the external stent has been standard care for
several years. Randomization was performed with a con-
cealed opaque envelope system prepared by an indepen-
dent statistician at the Erasmus MC, University Medical
Center, Rotterdam. Patients were randomized after intu-
bation in the operating room. As a result of the use of
an externalized stent, blinding was not possible. There
were no blocks and no stratification methods used dur-
ing randomization.
The Medical Ethics Committee of the Erasmus MC,
University Medical Center, Rotterdam, approved the
trial protocol (MEC-2013-196), and the study was regis-
tered at the (Dutch) Netherlands Trial Registry: Trial
NL4358 (NTR4498).
Surgical technique
The donor nephrectomy was performed with either a
fully laparoscopic, a robot-assisted, or hand-assisted
retroperitoneoscopic approach. The kidney recipients
underwent transplantation with an extraperitoneal
approach to the iliac fossa. Firstly, the renal vein was
anastomosed to the external iliac vein, followed by
the renal artery that was anastomosed to the external
iliac artery. Then, an extravesical ureteroneocystostomy
was performed, as described by Lich-Gregoir [10,11].
The detrusor muscle was closed over the anastomosis
with one or two interrupted absorbable sutures to
create a submucosal tunnel, with an antireflux mecha-
nism. The stent group received a 7-fr suprapubic
externalized single J stent (Teleflex), and it was
removed 9 days postoperatively. A transurethral uri-
nary bladder catheter was placed according to stan-
dard care in all patients; this catheter was removed
after 7 days. All patient had a nuclear renogram scan
and an ultrasound one day after surgery. Furthermore,
daily serum creatinine levels were determined during
hospital stay.
Power calculation
The SPLINT trial was designed as a noninferiority
study. It was powered to demonstrate that omitting a
stent would not lead to a relevant increase in the
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urological complication rate, that is, the percentage of
required PCN drainages. To show that the increase in
patients without a stent requiring a PCN is at most 5%
(noninferiority margin), 96 patients per arm were
required (one-side alpha = 0.025, power = 90%). This
calculation was based on the assumption that among
patients that received stents, 20% would require a PCN
[1], and among patients that received no stent, 9%
would require a PCN [2]. To allow room for a few
nonevaluable cases, we randomized 100 patients per
arm.
Definitions
Baseline data of the recipients included gender, age,
American Society of Anesthesiologists (ASA) classifica-
tion, number of previous transplantations, body mass
index (BMI), warm and cold ischemia times, and pre-
emptive transplantations (prior to starting dialysis). Our
primary outcome was a PCN insertion within
12 months. Indications for a PCN insertion were as fol-
lows: urinary leakage (detected with a nuclear renogram
scan or demonstrated by high creatinine levels in the
fluid excretion from the wound or from the drain) or a
rise in serum creatinine combined with hydronephrosis
(detected with ultrasound). Our secondary outcome was
graft function, based on the glomerular filtration rate
(GFR), duration of surgery, perioperative blood loss,
any surgical re-intervention performed within
<12 months of kidney transplantation (including
nonurological re-interventions), length of hospital stay,
hematuria (defined as macroscopic hematuria during
hospital admission), urinary tract infection (UTI), and
graft rejection <1 month after kidney transplantation.
UTI was scored in case of a urinary culture with a bac-
terial load of ≥105 CFU/ml that was treated with antibi-
otics. Rejection was scored if patients received
antirejection treatment (methylprednisolone intra-
venous, IVIG, alemtuzumab, r-ATG). History of smok-
ing included current or past smokers.
Quality of life questionnaires
We evaluated QOL, health state, work effort, and dis-
abilities in daily life with two validated questionnaires:
the Euro-Qol-5D and the Short Form survey 36 (SF-36)
[12,13]. All questionnaires were completed preopera-
tively and at different time points postoperatively (at 2
and 6 weeks and at 3, 6, 9, and 12 months). Repeated
QOL measurements were compared with a mixed-
effects model for repeated measurements.
Immunosuppressive treatment
Immunosuppressive treatments included intravenous
basiliximab as induction therapy, given on the day of
surgery and on day 4 post-transplantation. Postopera-
tive immunosuppression also included tacrolimus,
mycophenolate mofetil, and prednisone. The prednisone
was tapered off over time and discontinued at 4 months
after transplantation.
Statistical analysis
All analyses were performed with IBM SPSS Statistics
for Windows (version 21.0. Armonk, NY, USA: IBM
Corp) and R 3.5 [R Core Team (2012); a language and
environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria. ISBN 3-
900051-07-0, URL http://www.R-project.org/]. We per-
formed an intention-to-treat analysis. Therefore,
patients were analyzed in the group in which they were
originally allocated. For the primary parameter, we cal-
culated beta with a 95% confidence interval (95% CI)
using a generalized linear model for the risk difference
for binominal variable and univariate analysis of vari-
ance for continuous variable. As the number of urinary
leakage was 0, we were not able to use the generalized
linear model, here, we calculated an exact confidence
interval for a risk difference [14].
For secondary parameters: Continuous variables with
a distribution that is approximately normal are pre-
sented as the mean and standard deviation, and com-
parisons were evaluated with the independent t-test.
Variables with skewed distributions are presented as the
median (range), and comparisons were evaluated with
the Mann–Whitney U-test. Categorical variables are pre-
sented as numbers with percentages, and comparisons
were evaluated with the chi-square test.
Results
Baseline characteristics
Between April 2014 and March 2017, 200 patients were
included in the SPLINT trial. Because of perioperative
difficulties, one patient received a stent, although he
was allocated to the no-stent group. As this is an inten-
tion-to-treat analyses, this patient was analyzed in the
no-stent group. The cohort comprised 124 males and
76 females with a mean age of 54  13 years. Baseline
characteristics were comparable for both groups
(Table 1).
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Urological complications
In the no-stent group, 22 patients (22%) received a
PCN after transplantation (Table 2). Of this group, 11
patients received a PCN because of urinary leakage. Five
urinary leakages were resolved without further interven-
tions; four patients required a surgical re-intervention
to treat the urinary leakage; and two patients underwent
both an antegrade balloon dilatation and a surgical re-
intervention. One patient in the no-stent group with
urinary leakage did not receive a PCN, but underwent
immediate surgical repair. In the no-stent group,
another 11 patients received a PCN because of
hydronephrosis. Of these patients, eight did not require
an additional intervention, one patient underwent a bal-
loon dilatation, and two patients received both a bal-
loon dilatation and a surgical re-intervention. One
patient in the no-stent group with hydronephrosis
because of a blood clot in the ureter did not receive a
PCN, but underwent surgical repair directly.
In the stent group, eight patients (8%) received a
PCN after transplantation, all because of
hydronephrosis. One patient underwent balloon dilata-
tion, and two patients underwent a balloon dilatation,
followed by a surgical re-intervention.
To assess whether no stenting is noninferior to stent-
ing, we allowed an increase of at most 5% in the num-
ber of patients without stent requiring a PCN (i.e., a
noninferiority margin of 5%). There were more PCN
insertions in the no-stent group, 14% (95% CI 4.3–
23.7%). Moreover, compared to the stent group, the
no-stent group had more urinary leakages, 12% (95%
CI 5.4–21.3%); and surgical re-interventions because of
urological complications, 8% (95% CI 1.5–14.5%). As
the CI extends below the noninferiority margin, nonin-
feriority of no-stent placement had not been demon-
strated. The number of PCNs placed because of
hydronephrosis was similar between groups. Details are
shown in Fig. 1 and Table 2.
Overall outcome
There were no significant differences between the stent
and no-stent group regarding the duration of surgery,
Table 1. Baseline characteristics
Characteristic Total (N = 200) No stent (N = 100) Stent (N = 100) P-value
Recipient, gender N (%)
M 124 (62) 63 (63) 61 (61) 0.771
F 76 (38) 37 (37) 39 (39)
Recipient age, years; mean  SD 54  13 55  13 52  14 0.170
Donor gender, N (%)
M 81 (41) 45 (45) 36 (36) 0.195
F 119 (59) 55 (55) 64 (64)
Donor age, years; mean  SD 54  12 54  12 53  13 0.572
ASA, N (%)
2 28 (14) 12 (12) 16 (16) 0.524
3 164 (82) 85 (85) 79 (79)
4 8 (4) 3 (3) 5 (5)
Number of KTs, N (%)
1 173 (86) 90 (90) 83 (83) 0.239
2 19 (10) 6 (6) 13 (13)
3 8 (4) 4 (4) 4 (4)
Laparoscopic technique, N (%) 123 (62) 61 (61) 62 (62) 0.884
Recipient BMI, mean  SD 27  5 28  5 27  5 0.408
History of smoking, N (%) 123 (61) 59 (59) 64 (64) 0.467
Pre-emptive KT, N (%) 102 (51) 48 (48) 54 (54) 0.396
Residual urinary production, N (%) 172 (86) 83 (83) 89 (89) 0.221
Ureteral length, cm; mean  SD 9  2 9  2 9  2 0.367
First warm ischemia time, min; mean  SD 3  1 3  1 3  2 0.196
Cold ischemia time, min; mean  SD 140  29 142  31 139  27 0.494
Second warm ischemia time, min; mean  SD 20  7 20  7 20  8 0.876
ASA, American Society of Anesthesiologists; BMI, body mass index; F, female; KT, kidney transplantation; M, male; N, number;
SD, standard deviation.
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blood loss, total number of surgical re-interventions
within 12 months (including nonurological re-interven-
tions), UTIs, urosepsis, deaths, wound infections, and
readmissions within 1 and 12 months after transplanta-
tion. In the stent group, there were more patients with
macroscopic hematuria than in the no-stent group, 26%
(95% CI 13.1–38.9%). In addition, compared to the no-
stent group, more patients in the stent group required
treatment because of graft rejection within 1 month
after transplantation, 15% (95% CI 2.7–27.3%)
(Table 3). Stented patients had a longer hospital stay
because of our internal protocol (discharge only after
stent removal) (mean: 13  6 vs. 10  4 days). In the
no-stent group, one patient died of non-Hodgkin lym-
phoma. In the stent group, two patient died: one
because of respiratory insufficiency caused by Guillain–
Barre syndrome and the other patient because of cardiac
reasons.
Graft outcome
We did not detect any differences between both groups
regarding the mean GFR on days 7 or 14 or at 1, 3, 6,
or 12 months after transplantation (Table 4).
Quality of life questionnaires
We compared QOL outcomes correcting for baseline at
the various time points using a linear mixed model.
Besides a better Euro-Qol-5D in the no-stent group 2
and 6 weeks postoperative, we could not demonstrate
an effect of the stent (P = 0.56 for the multivariable test
for the SF-36 and P = 0.06 for the multivariable test for
the Euro-Qol-5D) (Tables 5 and 6).
Discussion
This randomized controlled trial in living-donor kidney
transplantation investigated the influence of stent versus
no-stent placement. We found more PCN insertions,
urinary leakages, and surgical re-interventions because
of urological complications in the no-stent group. In
the stent group, there were more hematuria and graft
rejection. In general, we could not demonstrate an effect
of the stent on quality of life, besides a better Euro-
Qol-5D result in the no-stent group 2 and 6 weeks
postoperative.
This trial was conducted to provide well-defined, evi-
dence-based arguments for ureteric stent placement in
kidney transplantation. Previously, five randomized con-
trolled trials [15–19] were conducted on stent place-
ment, but they differed in the use of living-donor or
deceased-donor kidneys, intravesical or extravesical
anastomoses, and the type of stent used. According to
those studies, stenting seemed to be favored, but it
remained uncertain whether stenting should be consid-
ered routine or only performed when strictly defined
criteria were met. A Cochrane review on this topic sup-
ported the use of ureteral stents, but they did not state
recommendations for duration and the type of stent
[4]. Timing of stent removal remains difficult. A
recently published meta-analysis supports stent removal
within three weeks postoperatively; however, this state-
ment was based on double J stents [20].
Previously, we investigated whether the type of anas-
tomosis (extravesical vs. intravesical; INEX trial) was a
risk factor for PCN insertion [21]. Both groups received
a ureteral stent, although a different stent than which
was used in the current SPLINT trial. We found no dif-
ference in the number of PCN insertions between
groups that received intravesical or extravesical anasto-
moses (20% vs. 20%). However, the number of UTIs
was lower in the extravesical group. Currently, our stan-
dard of care includes the extravesical anastomosis.
Based on the results of the current study, we are con-
vinced that ureteric stent placement with an extravesical
ureteroneocystostomy could reduce the number of uro-
logical complications in kidney transplantation. Only
Table 2. Urological complications within 12 months
Characteristics
Total
(N = 200)
No stent
(N = 100)
Stent
(N = 100)
Risk
difference (%) 95% CI
PCN insertion, N (%) 30 (15) 22 (22) 8 (8) 14 4.3 to 23.7
Urinary leakage, N (%) 12 (6) 12 (12) 0 (0) 12 5.4 to 21.3
Hydronephrosis, N (%) 20 (10) 12 (12) 8 (8) 4 4.3 to 12.3
Surgical re-intervention because of
urological complications, N (%)
12 (6) 10 (10) 2 (2) 8 1.5 to 14.5
Antegrade balloon dilatation, N (%) 8 (4) 5 (5) 3 (3) 2 3.4 to 7.4
CI, confidence interval; N, number; PCN, percutaneous nephrostomy insertion.
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8% of patients received PCN insertions in the stented
extravesical anastomosis group. This proportion was
considerably lower than the 20% in the above-men-
tioned INEX trial [21].
Although stent placement increased the duration of
ureteral anastomosis, it did not influence the total dura-
tion of surgery. However, the mean total hospital stay
was longer in the stent group than in the no-stent
Total recipients 
n = 200
No stent n = 100
No PCN
n = 76 (76%) 
PCN 
n = 22 (22%)
Urinary leakage 
n = 11 (50%)
No intervention 
n = 5
Surgical re-
intervention n = 4
Balloon 
dilatation and 
surgical re-
intervention
n = 2 
Hydronephrosis 
n = 11 (50%)
No intervention 
n = 8
Balloon 
dilatation n = 1
Balloon 
dilatation and 
surgical re-
intervention
n = 2
Direct surgical 
re-intervention 
n = 2 (2%)
Stent n = 100
No PCN 
n = 92 (92%)
PCN  
n = 8 (8%)
Urinary leakage 
n = 0 
(0%)
No intervention
n = 0
Hydronephrosis 
n = 8 (100%)
No intervention 
n = 5
Balloon 
dilatation n = 1
Balloon 
dilatation and 
surgical re-
intervention
n = 2 
Figure 1 Flowchart SPLINT trial. N, number; PCN, percutaneous nephrostomy.
Table 3. Overall outcome
Outcome Total (N = 200) No stent (N = 100) Stent (N = 100) P-value
Duration of surgery, min; mean  SD 116  36 114  39 119  34 0.314
Blood loss, ml; median (range) 150 (0–2000) 150 (0–2000) 150 (0–1300) 0.451
Any surgical re-intervention in <12 months, N (%) 34 (17) 21 (21) 13 (13) 0.132
Hematuria in <1 month, N (%) 126 (63) 50 (50) 76 (76) <0.001
UTI in <1 month, N (%) 47 (24) 27 (27) 20 (20) 0.243
Urosepsis in <1 month, N (%) 9 (5) 5 (5) 4 (4) 0.733
Wound infection in <1 month, N (%) 22 (11) 14 (14) 8 (8) 0.175
Rejection in <1 month, N (%) 57 (29) 21 (21) 36 (36) 0.019
Biopsy-proven rejection in <1 month, N (%) 40 (20) 11 (11) 29 (29) 0.001
Total length of hospital stay, days; mean  SD 11  5 10  4 13  6 <0.001
Readmission in <1 month, N (%) 47 (24) 27 (27) 20 (20) 0.243
Readmission in <12 months, N (%) 110 (55) 57 (57) 53 (53) 0.570
Number of readmissions per person
in <12 months; median (range)
1 (0–17) 1 (0–12) 1 (0–17) 0.563
Death <12 months, N (%) 3 (1.5) 1 (1) 2 (2) 0.561
N, number; SD, standard deviation; UTI, urinary tract infection.
Bold values are statistically significant.
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group. This is due to the fact that in our hospital,
stented patients were only discharged after stent
removal.
Remarkably, we found a higher number of rejections
in the stent group than in the no-stent group. These
patients had received antirejection treatments (intra-
venous methylprednisolone, IVIG, alemtuzumab, or r-
ATG) within 1 month after transplantation. We could
not find any explanation for this finding. We speculate
that, because patients with stents had prolonged hospi-
tal stays, rise of serum creatinine might have been
detected more rapidly, because of frequent in-hospital
evaluations, compared with outpatient visits. In addi-
tion, urine production can be monitored more accu-
rately in patients with externalized stents than in
patients without a stent; this monitoring might have led
to a relatively low threshold for biopsy. However, we
cannot completely disclaim that the stent (being a for-
eign body) could facilitate an immune response leading
to rejection. Note that there is no literature, which does
substantiate this.
This study had a few limitations. Most importantly,
the suprapubic externalized type of stent (single J stent)
used in this trial is not a stent commonly used. Most
transplant centers use the double J stent, and literature
indicated that the double J stent is also associated with
minor urological complications. Furthermore, we have a
relatively high number of PCN insertions compared to
literature. In our clinic, we have a low threshold to
place a PCN, as this is considered a minimally invasive
event. Even a mild hydronephrosis leads to PCN inser-
tion, either for therapeutically benefit or as diagnostic
tool before performing an biopsy. As in this trial the
data are collected prospectively, the database is more
complete and accurate, possibly resulting in a higher
percentage of complications than the complication rates
that are mentioned in other kinds of publications. Our
Table 4. Graft outcome
Renal function
after KT
mean  SD
No stent
(N = 100)
GFR ml/min
Stent
(N = 100)
GFR ml/min P-value
7 days 41  15 41  19 0.950
14 days 46  15 46  17 0.778
1 month 48  15 47  16 0.794
3 months 49  15 48  16 0.576
6 months 51  16 49  16 0.324
12 months 52  18 52  18 0.922
GFR, glomerular filtration rate; KT, kidney transplantation;
SD, standard deviation.
Table 5. SF-36 questionnaire
Time point
No stent
95%CI
Stent
95%CI
Delta
P-valueMean Lower limit Upper limit Mean Lower limit Upper limit Mean
2 weeks 21.2 13.3 29.2 18.1 10.3 26.0 3.1 0.272
6 weeks 30.3 22.3 38.3 26.9 18.9 34.9 3.5 0.241
3 months 32.9 24.7 41.1 35.7 27.6 43.8 2.8 0.381
6 months 35.8 27.7 44.0 34.7 26.6 42.8 1.1 0.720
9 months 40.2 31.9 48.5 38.7 30.5 47.0 1.4 0.666
12 months 40.8 32.6 49.0 39.3 31.2 47.4 1.5 0.639
Preoperative scores 59.4 55.3 63.4 57.9 53.9 62.0 1.5
Table 6. Euro-Qol-5D questionnaire
Postoperative time point
No stent
95% CI
Stent
95% CI
Delta
P-valueMean Lower limit Upper limit Mean Lower limit Upper limit Mean
2 week 0.17 0.22 0.12 0.24 0.30 0.19 0.07 0.030
6 weeks 0.07 0.12 0.02 0.14 0.20 0.09 0.07 0.037
3 months 0.07 0.12 0.02 0.07 0.13 0.02 0.00 0.917
6 months 0.06 0.11 0.01 0.10 0.15 0.04 0.04 0.230
9 months 0.07 0.12 0.02 0.05 0.11 0.00 0.02 0.628
12 months 0.08 0.13 0.03 0.08 0.14 0.02 0.00 0.984
Preoperative scores 0.17 0.21 0.12 0.21 0.25 0.16 0.04
Bold values are statistically significant.
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number of re-interventions because of urological com-
plications is comparable to literature. Cost-effectiveness
data were collected during this trial and will be pub-
lished separately.
A previous retrospective study by Vogel et al. that
included 76 patients compared 43 externalized stents
and 33 double J stents. They reported that the inci-
dences of leakage from the ureteroneocystostomy were
13.9% for externalized stents and 0% for double J
stents. Furthermore, they found a 2-day reduction in
hospital stay time with the internal stent [22]. Gomes
et al. also retrospectively reviewed the use of external-
ized stents, internal stents, and no stent, in 2061 recipi-
ents of kidney transplants. In their cohort, the
incidences of urological complications were 17.3% in
the externalized stent group, 8.4% in the no-stent
group, and 5.4% in the double J stent group
(P < 0.0005) [23]. The authors concluded that external-
ized stents should be avoided, because they were associ-
ated with a high urological complication rate. Guleria
et al. [24] also reduced urological complications by
changing their technique from no stent (7.7%) to a
double J stented (for a period of 6 weeks) ureteroneo-
cystostomy (3.8%). Unfortunately, those studies had
retrospective designs. Furthermore, patients with an
external stent do not need an additional cystoscopy for
stent removal. By lowering the number of interventions,
external stents may reduce patients’ morbidity and
costs. Therefore, we recently started a new trial at the
Erasmus MC, University Medical Center, Rotterdam, in
which we investigate whether single J or double J stent-
ing is superior in reducing the number of urological
complications.
In this trial, noninferiority has not been demon-
strated for no-stent placement in relation to the number
of urological complications.
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